{"title":"更正:建立新型癌症特异性抗 HER2 单克隆抗体 H2Mab-250/H2CasMab-2 治疗乳腺癌'',Kaneko 等著,《免疫诊断和免疫疗法中的单克隆抗体》,2024;43(2):35-43; doi: 10.1089/mab.2023.0033。","authors":"","doi":"10.1089/mab.2023.0033.correx","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"4 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to: Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers'' by Kaneko et al. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2024;43(2):35-43; doi: 10.1089/mab.2023.0033.\",\"authors\":\"\",\"doi\":\"10.1089/mab.2023.0033.correx\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":53514,\"journal\":{\"name\":\"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy\",\"volume\":\"4 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/mab.2023.0033.correx\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/mab.2023.0033.correx","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Correction to: Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers'' by Kaneko et al. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2024;43(2):35-43; doi: 10.1089/mab.2023.0033.